ReviewCureus2026
Clinical Scenarios in Hospitalized Patients With Hemophilia.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophilia is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Despite therapeutic advances that have extended life expectancy, hospitalized patients with hemophilia present complex clinical challenges. This narrative review, illustrated with four structured clinical cases, addresses the most common scenarios encountered in the management of hospitalized patients with hemophilia: acute bleeding, perioperative management without inhibitors, perioperative management with inhibitors, and antithrombotic therapy in patients with comorbid cardiovascular disease. Factor replacement remains the cornerstone of therapy, with target levels and dosing duration determined by bleeding site and procedure type. Inhibitor development occurs in up to 30% of hemophilia A patients and necessitates the use of bypassing agents (recombinant activated factor VII or activated prothrombin complex concentrate). Perioperative management requires a multidisciplinary approach with 24-hour laboratory and blood bank availability. Cardiovascular comorbidities, including ischemic heart disease and atrial fibrillation, occur at rates comparable to the general population in aging patients with hemophilia; antithrombotic therapy must be individualized according to baseline factor levels, bleeding phenotype, and inhibitor status. Left atrial appendage closure represents a viable alternative to long-term anticoagulation in selected high-risk patients. Optimal management of hospitalized patients with hemophilia demands individualized, multidisciplinary care. Clinicians should be familiar with factor replacement protocols, inhibitor detection and management strategies, and the growing challenge of balancing bleeding risk with antithrombotic therapy in an aging hemophilia population. These practical considerations are essential for hospital-based clinicians involved in the care of this complex patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.